Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM)‘s stock had its “buy” rating reissued by investment analysts at Roth Capital in a research note issued to investors on Wednesday. They currently have a $5.00 price objective on the stock. Roth Capital’s target price would suggest a potential upside of 275.94% from the company’s previous close.
ATNM has been the topic of a number of other reports. Zacks Investment Research upgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Monday, June 6th. HC Wainwright restated a “buy” rating on shares of Actinium Pharmaceuticals in a report on Thursday, June 2nd. Finally, FBR & Co restated a “buy” rating on shares of Actinium Pharmaceuticals in a report on Monday, June 6th.
Actinium Pharmaceuticals (NYSEMKT:ATNM) opened at 1.33 on Wednesday. The company has a 50 day moving average of $1.71 and a 200-day moving average of $1.81. The firm’s market cap is $63.46 million. Actinium Pharmaceuticals has a one year low of $1.29 and a one year high of $3.50.
In other Actinium Pharmaceuticals news, major shareholder Sloan-Kettering Cance Memorial sold 192,927 shares of the company’s stock in a transaction dated Wednesday, August 31st. The shares were sold at an average price of $1.83, for a total value of $353,056.41. Following the transaction, the insider now directly owns 4,878,988 shares in the company, valued at approximately $8,928,548.04. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATNM. BlackRock Institutional Trust Company N.A. raised its position in shares of Actinium Pharmaceuticals by 11.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 462,683 shares of the company’s stock valued at $819,000 after buying an additional 47,131 shares during the last quarter. BlackRock Fund Advisors raised its position in shares of Actinium Pharmaceuticals by 31.5% in the second quarter. BlackRock Fund Advisors now owns 102,003 shares of the company’s stock valued at $181,000 after buying an additional 24,453 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Actinium Pharmaceuticals by 19.2% in the second quarter. Vanguard Group Inc. now owns 1,581,228 shares of the company’s stock valued at $2,798,000 after buying an additional 254,318 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of Actinium Pharmaceuticals during the second quarter valued at $247,000.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.